Online citations, reference lists, and bibliographies.
← Back to Search

ENHANCEMENT OF NASAL ABSORPTION OF CALCITONIN LOADED IN LIPOSOMES

S. Law, K. Huang, V. Chou, J. Cherng
Published 2001 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Intranasal administration of calcitonin-containing liposomes in rabbits was investigated to evaluate the in vivo calcitonin absorption performance. Plasma calcitonin concentrations and calcium levels were measured and pharmacokinetic parameters were calculated. The bioavailability of calcitonin resulted from the intranasal delivery formulations demonstrated an order of calcitonin-containing positively charged liposomes > calcitonin-containing negatively charged liposomes > calcitonin solution. The significant enhancement of bioavailability of calcitonin for positively charged liposomes may be due to the charge interaction of positively charged liposomes with the negatively charged mucosa surface. Marked accumulation of positively charged liposomes was found on the negatively charged nasal mucosa surface. The retention of positively charged liposomes on the nasal mucosa resulted in an increase of residence time with high local concentration of calcitonin for increase of absorption.
This paper references
Book review: Inhalation Delivery of Therapeutic Peptides and Proteins. Adjei AL, Gupta PK, eds. Marcel Dekker, New York
K. Taylor (1997)
10.3109/10717549809031388
The influence of the enhancer dimyristoylphosphatidylglycerol and formulation factors on the nasal absorption of salmon calcitonin.
R. Dua (1998)
10.1007/BF00558516
Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents
A. Pontiroli (2004)
10.1016/0378-5173(95)04115-X
Bioadhesive and formulation parameters affecting nasal absorption
P. Dondeti (1996)
Intranasal Delivery of Peptides and Proteins. In Inhalation delivery of therapeutic peptides and proteins
L Illum
10.1055/S-2007-1003642
Liposome-entrapped calcitonin and parathyroid hormone are orally effective in rats.
Masao Fukunaga (1991)
Chitosan as a Novel Delivery System for Peptide Drugs
L. Illum (1994)
10.1016/0378-5173(87)90216-X
Bioadhesive microspheres as a potential nasal drug delivery system
L. Illum (1987)
10.1111/j.2042-7158.1985.tb05024.x
Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel
K. Morimoto (1985)
10.1016/0168-3659(90)90015-L
Intranasal administration of calcitonin and of other peptides: Studies with different promoters
A. Pontiroli (1990)
10.1007/978-3-642-79511-4_5
Oral Route of Peptide and Protein Drug Delivery
V. Lee (1995)
10.1016/S0378-5173(98)00367-6
Evaluation of the clearance characteristics of bioadhesive systems in humans.
R. Soane (1999)
10.3109/08982108909036000
Adhesion of Positively Charged Liposomes to Mucosal Tissues
L. S. Guo (1989)
10.1023/A:1016051600828
Enhancement of Nasal Salmon Calcitonin Absorption by Lauroylcarnitine Chloride in Rats
S. Kagatani (2004)
Liposomes in topical drug delivery.
H. E. Schaeffer (1982)
10.1007/BF02175097
Liposomes and biotherapeutics
G. Storm (1991)
Effect of Liposomes on Calcitonin Penetration Through the Nasal Mucosa
S. L. Law (2000)
A Profile of Sandoz's Salmon Calcitonin
Calcitonin-Sandoz Miacalcic (1989)
10.1080/02652040010000334
Characterization of calcitonin-containing liposome formulations for intranasal delivery.
S. Law (2001)
10.1016/S0168-3659(00)00369-2
Preparation of desmopressin-containing liposomes for intranasal delivery.
S. Law (2001)
Intranasal Delivery of Peptides and Proteins
L. Illum (1997)
10.1016/0378-5173(92)90353-4
In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers
C. Lehr (1992)
10.1089/JOP.1986.2.67
Topical ocular drug delivery: recent developments and future challenges.
V. Lee (1986)
10.1210/ENDO-115-2-757
Liposome entrapment enhances the hypocalcemic action of parenterally administered calcitonin.
Masao Fukunaga (1984)



This paper is referenced by
10.1007/978-1-4020-6289-6
Nanomaterials and nanosystems for biomedical applications
M. R. Mozafari (2007)
RECENT ADVANCES IN NASAL FORMULATIONS AND DEVICES USED IN PULMONARY DRUG DELIVERY
T. P. Kumar (2013)
10.1007/978-1-4020-6289-6_6
Alternative Applications for Drug Delivery: Nasal and Pulmonary Routes
A. Ozer (2007)
MULTIFUNCTIONAL NANOCARRIERS ENCAPSULATING ANTI-ALZHEIMER DRUG FOR NASAL DELIVERY TO CENTRAL NERVOUS SYSTEM
Scienze Farmaceutiche (2012)
10.7150/thno.46691
Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients
Rasha Itani (2020)
10.1002/9780470571224.PSE521
Routes of Delivery for Biological Drug Products
D. Irvine (2013)
10.1007/978-1-60761-529-3_8
Vesicular Systems for Intranasal Drug Delivery
I. Alsarra (2010)
PULMONARY DRUG DELIVERY SYSTEM: REVIEW
N. K. Chaturvedi (2013)
NOVEL NASAL DRUG DELIVERY SYSTEMA REVIEW
J. Joysa Ruby (2014)
10.1517/17425247.2012.735658
Liposomal delivery of proteins and peptides
Janani Swaminathan (2012)
10.1016/j.lfs.2020.118336
COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic
Valamla Bhavana (2020)
10.1016/j.ejpb.2017.10.008
In situ mucoadhesive‐thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin
P. Mura (2018)
10.1016/j.ejps.2013.07.006
The effect of polymer coatings on physicochemical properties of spray-dried liposomes for nasal delivery of BSA.
K. Chen (2013)
10.1016/S1773-2247(06)50061-9
Chitosan nanocapsules: a new carrier for nasal peptide delivery
C. Prego (2006)
PRELIMINARY STUDIES ON BRAIN TARGETING OF INTRANASAL ATOMOXETINE LIPOSOMES
A. V. Vaidya (2016)
10.18433/J3NC79
Intranasal drug delivery: how, why and what for?
A. Pires (2009)
DRUG DELIVERY AND ITS DEVELOPMENTS FOR PULMONARY SYSTEM
R. Sunitha (2011)
10.6092/UNIBO/AMSDOTTORATO/6468
Strategie formulative per la veicolazione nasale di farmaci
Bruno Saladini (2014)
10.1016/j.biotechadv.2015.01.010
Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers.
M. Witting (2015)
10.1016/j.biomaterials.2012.08.070
Airway delivery of peptides and proteins using nanoparticles.
C. Dombu (2013)
10.1016/j.ijpharm.2009.10.031
Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride.
L. D. du Plessis (2010)
10.1089/jamp.2013.1049
Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Janani Swaminathan (2014)
10.3109/08982104.2014.899366
Effect of lyophilization on liposomal encapsulation of salmon calcitonin
Janani Swaminathan (2014)
10.3109/08982104.2014.899369
Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride
G. Corace (2014)
10.1517/17425247.2011.588204
Intranasal delivery of therapeutic proteins for neurological diseases
F. Malerba (2011)
10.2174/0929867326666190827151741
Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery.
Areen Alshweiat (2019)
Non-invasive Systemic Drug Delivery via Nasal Route: A Review
R. C. Dhakar (2011)
10.4155/tde.13.31
Strategies for enhanced peptide and protein delivery.
M. McCrudden (2013)
Semantic Scholar Logo Some data provided by SemanticScholar